Lv2
142 积分 2022-12-05 加入
Hidradenitis suppurativa and bimekizumab: Looking to the future
3小时前
已关闭
What’s so hard about RNA-targeting drug discovery?
6天前
已完结
Complement in neurological disorders and emerging complement-targeted therapeutics
6天前
已完结
Clinical promise of next-generation complement therapeutics
7天前
已完结
Discovery and Characterization of a New Class of C5aR1 Antagonists Showing In Vivo Activity
7天前
已完结
Vilobelimab to improve clinical outcomes of moderate-to-severe hidradenitis suppurativa through an adjunctive effect on draining tunnels: Results of the SHINE double-blind, placebo-controlled randomised trial
7天前
已关闭
Funktionelle Charakterisierung der Kalzium/Calmodulin-abhängigen Proteinkinase-II-δ (CaMKIIδ)-Knockout-Maus
11天前
已关闭
Ruxolitinib as a CaMKII inhibitor for treatment of cardiac arrhythmias: Applications and prospects
12天前
已完结
Activity of cAMP-dependent protein kinase and Ca2+/calmodulin-dependent protein kinase in failing and nonfailing human hearts
14天前
已完结
First-in-Human Study on Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Escalating Doses of HEC88473, a Novel Dual GLP-1 and FGF21 Receptor Agonist in Healthy and Obese Chinese Subjects
1个月前
已完结
皖公网安备34019202002308
